Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits

被引:11
作者
Fujita, Eriko [1 ]
Teramura, Yoshinori [2 ]
Mitsugi, Koichi [3 ]
Ninomiya, Shin-Ichi [3 ]
Iwatsubo, Takafumi [1 ]
Kawamura, Akio [1 ]
Kamimura, Hidetaka [1 ]
机构
[1] Astellas Pharma Inc, Drug Metab Res Labs, Itabashi Ku, Tokyo 1748511, Japan
[2] Astellas Pharma Inc, Pharma Res & Technol Labs, Shizuoka, Japan
[3] Daiichi Pure Chem Co Ltd, ADME TOX Res Inst, Ibaraki, Japan
关键词
D O I
10.1089/jop.2007.0086
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to investigate the absorption, distribution, and excretion of radioactivity in male rabbits after a single or repeated instillation of C-14-labeled tacrolimus (FK506) ophthalmic suspension or an intravenous (i.v.) administration of C-14-FK506. Methods: The 0.3% C-14-FK506 suspension was administered in single and repeated (three times, 5-min intervals) instillation studies, and 1 mg/kg of C-14-FK506 was administered in the i.v. dose study. Results: Results for single and repeated instillation studies were similar. In eyeball microautoradiograms, 15 min after dosing, the level of radioactivity in the cornea was the highest, followed by conjunctiva. After 1 h, little specific distribution was detected in the corneal epithelium, stroma, or Descemet's membrane. At 24 h, the level of radioactivity in the cornea decreased. Whole-body autoradiograms showed that the radioactivity was distributed to the digestive tract through the nasal meatus and esophagus and then was excreted into the feces. In the i.v. dose study, the distribution of radioactivity in whole-body autoradiographs was similar to that in quantitative tissue distribution measurements. The excretion of radioactivity in the urine and feces up to 168 h were 4.5 and 94.9%, respectively. Conclusions: After the ocular instillation, FK506 is first absorbed in the cornea, conjunctiva, and nasolacrimal duct, and then the rest is distributed to digestive tract through the nasal meatus and esophagus, after which it is excreted mainly into the feces.
引用
收藏
页码:333 / 343
页数:11
相关论文
共 17 条
  • [1] ANDERSSON J, 1992, IMMUNOLOGY, V75, P136
  • [2] Successful treatment of myasthenia gravis with tacrolimus
    Evoli, A
    Di Schino, C
    Marsili, F
    Punzi, C
    [J]. MUSCLE & NERVE, 2002, 25 (01) : 111 - 114
  • [3] IWASAKI K, 1993, DRUG METAB DISPOS, V21, P971
  • [4] IWASAKI K, 1995, XENOBIOTIC METAB DIS, V10, P837
  • [5] FK-506, A NOVEL IMMUNOSUPPRESSANT ISOLATED FROM A STREPTOMYCES .1. FERMENTATION, ISOLATION, AND PHYSICOCHEMICAL AND BIOLOGICAL CHARACTERISTICS
    KINO, T
    HATANAKA, H
    HASHIMOTO, M
    NISHIYAMA, M
    GOTO, T
    OKUHARA, M
    KOHSAKA, M
    AOKI, H
    IMANAKA, H
    [J]. JOURNAL OF ANTIBIOTICS, 1987, 40 (09) : 1249 - 1255
  • [6] Lauerma AI, 1997, SKIN PHARMACOL, V10, P230
  • [7] Ophthalmic drug delivery systems - Recent advances
    Le Bourlais, C
    Acar, L
    Zia, H
    Sado, PA
    Needham, T
    Leverge, R
    [J]. PROGRESS IN RETINAL AND EYE RESEARCH, 1998, 17 (01) : 33 - 58
  • [8] Tacrolimus therapy in rheumatoid arthritis
    McCarey, DW
    Capell, HA
    Madhok, R
    [J]. RHEUMATOLOGY, 2004, 43 (08) : 946 - 948
  • [9] TACROLIMUS OINTMENT FOR ATOPIC-DERMATITIS
    NAKAGAWA, H
    ETOH, T
    ISHIBASHI, Y
    HIGAKI, Y
    KAWASHIMA, M
    TORII, H
    HARADA, S
    [J]. LANCET, 1994, 344 (8926) : 883 - 883
  • [10] TACROLIMUS - A REVIEW OF ITS PHARMACOLOGY, AND THERAPEUTIC POTENTIAL IN HEPATIC AND RENAL-TRANSPLANTATION
    PETERS, DH
    FITTON, A
    PLOSKER, GL
    FAULDS, D
    [J]. DRUGS, 1993, 46 (04) : 746 - 794